
BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
Vote In favor of Your Favored Language Interpretation Administration - 2
NASA unveils close-up pictures of the comet popping by from another star - 3
Figure out How to Store Your Gold Ventures: A Thorough Aide safely - 4
Judge sets $60K bond for Florida congresswoman accused of stealing $5M in COVID-19 funds - 5
Vote in favor of the field action that revives your psyche and soul!
One third of Spanish pork export certificates blocked since swine fever outbreak, minister says
Step by step instructions to Streamline Your Dozing Involvement in a Savvy Bed
Which salad do you believe is a definitive group pleaser? Vote!
Figure out How to Analyze Medical attendant Compensation Patterns Across Different Specializations
Doctors seek to understand why quitting antidepressants causes withdrawal for some
Surveys of Thrillers That Re-imagined the Class
From Fledgling to Master: Self-awareness in a Side interest
Several Israelis attempt to cross into Gaza, escorted back to Israel by IDF
South Korea launches Earth-observation satellite on homegrown Nuri rocket













